| 1.1781 -0.012 (-1%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.47  |
1-year : | 1.63 |
| Resists | First : | 1.26 |
Second : | 1.39 |
| Pivot price | 1.19  |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 1.21 |
MA(20) : | 1.18 |
| MA(100) : | 1.9 |
MA(250) : | 7.65 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.8 |
D(3) : | 51.1 |
| RSI | RSI(14): 43.4 |
|||
| 52-week | High : | 24.65 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CMND ] has closed above bottom band by 45.1%. Bollinger Bands are 75.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 55 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.2 - 1.21 | 1.21 - 1.22 |
| Low: | 1.13 - 1.14 | 1.14 - 1.15 |
| Close: | 1.16 - 1.18 | 1.18 - 1.19 |
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Wed, 17 Apr 2024
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the ... - GlobeNewswire
Tue, 09 Apr 2024
Clearmind Medicine CEO Issues Letter to Shareholders - Yahoo Canada Finance
Tue, 09 Apr 2024
Clearmind Medicine CEO Issues Letter to Shareholders - Yahoo Finance
Tue, 19 Mar 2024
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China - Yahoo Finance
Wed, 13 Mar 2024
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ... - Yahoo Finance
Fri, 23 Feb 2024
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 179 (K) |
| Shares Short P.Month | 231 (K) |
| EPS | -31.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.6 % |
| Return on Equity (ttm) | -181.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|